InsiderTrades.com logo
Adam Scott Levy net worth and biography
  • Phone
  • Email
  • Website

Adam Levy Biography and Net Worth

Chief Financial Officer of Mineralys Therapeutics

Adam Levy has served as our Chief Financial Officer and Chief Business Officer since March 2022. Prior to joining Mineralys, he was the Chief Financial Officer at Sanifit Therapeutics until the company was acquired by Vifor Pharma in 2022. Previously, Adam served as the Chief Business Officer at Brickell Biotech from 2019 to 2020 and led the organization’s financial operations transition as it became a publicly listed company on Nasdaq. Prior to that, he served as the Chief Business Officer at miRagen Therapeutics from 2016 to 2019, where he was responsible for a variety of functions including financial strategy, investor relations, business development, legal affairs, intellectual property, project and program management, and human resources. Between 2000 and 2016, Mr. Levy held multiple investment banking positions at Merrill Lynch, Jefferies Group and Wedbush Securities. Mr. Levy received a B.S. in Business Management and Marketing from Cornell University.

What is Adam Scott Levy's net worth?

The estimated net worth of Adam Scott Levy is at least $2.87 million as of April 11th, 2025. Mr. Levy owns 215,340 shares of Mineralys Therapeutics stock worth more than $2,872,636 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Levy may own. Additionally, Mr. Levy receives an annual salary of $655,580.00 as Chief Financial Officer at Mineralys Therapeutics. Learn More about Adam Scott Levy's net worth.

How old is Adam Scott Levy?

Mr. Levy is currently 46 years old. There are 3 older executives and no younger executives at Mineralys Therapeutics. The oldest executive at Mineralys Therapeutics is Dr. David M. Rodman M.D., Chief Medical Officer, who is 69 years old. Learn More on Adam Scott Levy's age.

What is Adam Scott Levy's salary?

As the Chief Financial Officer of Mineralys Therapeutics, Inc., Mr. Levy earns $655,580.00 per year. There are 2 executives that earn more than Mr. Levy. The highest earning executive at Mineralys Therapeutics is Mr. Jon Congleton, CEO & Director, who commands a salary of $775,770.00 per year. Learn More on Adam Scott Levy's salary.

How do I contact Adam Scott Levy?

The corporate mailing address for Mr. Levy and other Mineralys Therapeutics executives is , , . Mineralys Therapeutics can also be reached via phone at 888-378-6240 and via email at investorrelations@mineralystx.com. Learn More on Adam Scott Levy's contact information.

Has Adam Scott Levy been buying or selling shares of Mineralys Therapeutics?

During the past quarter, Adam Scott Levy has sold $129,729.42 of Mineralys Therapeutics stock. Most recently, Adam Scott Levy sold 10,757 shares of the business's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.06, for a transaction totalling $129,729.42. Following the completion of the sale, the chief financial officer now directly owns 215,340 shares of the company's stock, valued at $2,597,000.40. Learn More on Adam Scott Levy's trading history.

Who are Mineralys Therapeutics' active insiders?

Mineralys Therapeutics' insider roster includes Jon Congleton (CEO), Adam Levy (Chief Financial Officer), and David Rodman (Chief Medical Officer). Learn More on Mineralys Therapeutics' active insiders.

Are insiders buying or selling shares of Mineralys Therapeutics?

In the last twelve months, Mineralys Therapeutics insiders bought shares 2 times. They purchased a total of 1,896,296 shares worth more than $25,599,996.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 880,592 shares worth more than $11,566,301.71. The most recent insider tranaction occured on April, 14th when insider David Malcom Rodman sold 11,366 shares worth more than $165,147.98. Insiders at Mineralys Therapeutics own 33.2% of the company. Learn More about insider trades at Mineralys Therapeutics.

Information on this page was last updated on 4/14/2025.

Adam Scott Levy Insider Trading History at Mineralys Therapeutics

See Full Table

Adam Scott Levy Buying and Selling Activity at Mineralys Therapeutics

This chart shows Adam Scott Levy's buying and selling at Mineralys Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$130ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Mineralys Therapeutics Company Overview

Mineralys Therapeutics logo
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $13.34
Low: $12.90
High: $13.97

50 Day Range

MA: $12.92
Low: $8.76
High: $16.87

2 Week Range

Now: $13.34
Low: $8.24
High: $18.38

Volume

822,303 shs

Average Volume

426,510 shs

Market Capitalization

$865.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A